- Home
- STTK vs HYB Comparison
STTK vs HYB Comparison
Compare STTK & HYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- HYB
- Stock Information
- Founded
- STTK 2016
- HYB 1987
- Country
- STTK United States
- HYB United States
- Employees
- STTK N/A
- HYB N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- HYB Investment Managers
- Sector
- STTK Health Care
- HYB Finance
- Exchange
- STTK Nasdaq
- HYB Nasdaq
- Market Cap
- STTK 173.6M
- HYB 193.3M
- IPO Year
- STTK 2020
- HYB 1999
- Fundamental
- Price
- STTK $3.63
- HYB $8.26
- Analyst Decision
- STTK Strong Buy
- HYB
- Analyst Count
- STTK 3
- HYB 0
- Target Price
- STTK $10.67
- HYB N/A
- AVG Volume (30 Days)
- STTK 123.5K
- HYB 39.6K
- Earning Date
- STTK 11-07-2024
- HYB 01-01-0001
- Dividend Yield
- STTK N/A
- HYB 6.67%
- EPS Growth
- STTK N/A
- HYB N/A
- EPS
- STTK N/A
- HYB N/A
- Revenue
- STTK $4,123,999.00
- HYB N/A
- Revenue This Year
- STTK $164.45
- HYB N/A
- Revenue Next Year
- STTK N/A
- HYB N/A
- P/E Ratio
- STTK N/A
- HYB N/A
- Revenue Growth
- STTK 380.09
- HYB N/A
- 52 Week Low
- STTK $1.33
- HYB $6.23
- 52 Week High
- STTK $11.76
- HYB $7.41
- Technical
- Relative Strength Index (RSI)
- STTK 50.77
- HYB 65.38
- Support Level
- STTK $3.64
- HYB $8.22
- Resistance Level
- STTK $3.94
- HYB $8.31
- Average True Range (ATR)
- STTK 0.22
- HYB 0.08
- MACD
- STTK 0.04
- HYB -0.03
- Stochastic Oscillator
- STTK 53.42
- HYB 46.43
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About HYB New America High Income Fund Inc. (The)
New America High Income Fund Inc is a diversified, closed‐end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.